NovaBay Pharmaceuticals, Inc.
NBY
$0.6148
$0.01482.47%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 338.64% | 70.50% | 31.02% | 22.15% | -84.82% |
| Total Depreciation and Amortization | -42.71% | 0.00% | 0.00% | 16.99% | 638.46% |
| Total Amortization of Deferred Charges | -93.73% | -99.47% | -78.10% | -31.95% | -- |
| Total Other Non-Cash Items | -61.83% | -103.72% | -97.06% | 8.71% | 3,742.22% |
| Change in Net Operating Assets | 401.50% | -21.03% | -891.96% | 133.77% | 280.00% |
| Cash from Operations | 1,476.41% | -19.12% | -466.21% | 68.64% | 56.05% |
| Capital Expenditure | -- | 100.00% | -100.00% | 0.00% | 84.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -100.00% | 0.00% | 84.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.28% | 100.00% | -36.92% | -222.28% | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9,452.63% | -100.00% | -- | 67.35% | -- |
| Cash from Financing | -186.10% | 2,023.08% | 462.05% | -119.58% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -78.64% | -- | -- | -- |
| Net Change in Cash | 714.92% | -35.69% | 102.13% | -264.42% | 19.52% |